Acute Safety and Pharmacokinetics of Intravenous Busulfan When Used with Oral Busulfan and Cyclophosphamide as Pretransplantation Conditioning Therapy: A Phase I Study

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 5 A, 2000, Pages 548-554

  Andersson, Borje S ^a,e   Madden, Timothy ^a   Tran, Hai T ^a   Hu, Wendy W ^b   Blume, Karl G ^b   Chow, Diana S L ^c   Champlin, Richard E ^a   Vaughan, William P ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone marrow transplantation; Cyclophosphamide; IV busulfan; Pharmacokinetics; Pretransplantation conditioning therapy

Indexed keywords

ACETAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DRUG CARRIER; MACROGOL DERIVATIVE; N,N DIMETHYLACETAMIDE; SOLVENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; SAFETY;

ACETAMIDES; ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BUSULFAN; CYCLOPHOSPHAMIDE; DRUG CARRIERS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; SAFETY; SOLVENTS; TRANSPLANTATION CONDITIONING;

EID: 0034567061     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70064-4     Document Type: Article

References (46)

1. Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe Moelle Osseuse. Blood. 1992;79:2578-2582.
2. Blume KG, Kopecky KJ, Hensley-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparative regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood. 1993;81:2187-2193.
3. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036-2043.
4. Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Marrow Transplantation Group. Blood. 1994;83: 2723-2730.
5. Devergie A, Blaise D, Attal M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood. 1995;85:2263-2268.
6. Grochow LB, Jones JJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61.
7. Vassal G, Gouyette A, Hartmann O, et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemotber Pharmacol. 1989;24:386-390.
8. Hassan M, Öberg G, Ehrsson H, et al. Pharmacokinetic and metabolic studies of high-dose busulfan in adults. Eur J Clin Pharmacol. 1989;36:525-530.
9. Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood. 1990;75:1723-1727.
10. Hassan M, Oberg G, Bekassy AN, et al. Pharmacokinetics of high-dose busulfan in relation to age and chronopharmacology. Cancer Chemother Pharmacol. 1991;28:130-134.
11. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood. 1992;79:2475-2479.
12. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20:18-25.
13. Vassal G, Challine D, Koscielny S, et al. Chronopharmacology of high-dose busulfan in children. Cancer Res. 1993;53:1534-1537.
14. Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability. Blood. 1994;84:2144-2150.
15. Hassan M. Busulphan. In: Grochow LB, Ames NM, eds. A Clinician's Guide to Chemotherapy, Pharmacokinetics, and Pharmacodynamics. Baltimore, MD: Williams and Wilkins, 1997;189-208.
16. Schulman HM, Hinterger W. Hepatic veno-occlusive disease: liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant. 1992;10:197-214.
17. MacDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993; 118:255-264.
18. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230.
19. Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990;50:6203-6207.
20. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31-42.
21. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055-3060.
22. Peters WP, Henner WD, Grochow LB, et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res. 1987;47:6402-6406.
23. Andersson BS, Bhagwatwar H, Chow DS-L, inventors. Parenteral busulfan for treatment of malignant disease. US patent 5 430 057. July 4, 1995.
24. Bhagwatwar H, Phadungpojna S, Chow DS-L, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol. 1996;37:401-408.
25. Phadungpojna S, Chow DS-L, Reardan DT, Champlin RE, Andersson BS. Pharmacokinetics and toxicity of parenteral busulfan in dogs [abstract]. Proc Am Assoc Cancer Res. 1996;37:2528.
26. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70:1382-1388.
27. Busulfex (Busulfan) Injection: A Monograph. Minnetonka, MN: Orphan Medical; 1999.
28. Henner WD, Furlong EA, Flaherty MD, et al. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr. 1987;416:426-432.
29. Pawlowska AB, Blazer BR, Angelucci E, et al. Relationship of plasma pharmacokinetics of high-dose busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant. 1997;20:915-920.
30. Chow DS-L, Bhagwatwar HP, Phadungpojna S, Andersson BS. Stability-indicating high-performance liquid chromatographic assay of busulfan in aqueous and plasma samples. J Chromatogr B Biomed Appl. 1997;704:277-288.
31. Parzen E, Tanabe K, Kitagawa G, eds. Perspectives in Statistics: Selected Papers of Hirotugu Akiake (Springer Series in Statistics). New York, NY: Springer-Verlag; 1998.
32. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetics. Comput Methods Programs Biomed. 1979;9:115-134.
33. Schuler US, Ehrsam M, Schneider A, et al. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haemopoietic stem cell transplantation. Bone Marrow Transplant. 1998;22:241-244.
34. m-AMSA. NCI Investigational Drugs; Chemical Information. Washington, DC: US Department of Health and Human Services; 1984:134-135. NIH publication No. 84-2141.
35. Vumon (teniposide) for Injection Concentrate [package insert]. Bristol Laboratories, a Bristol Meyers Squibb Company.
36. Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated L-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer. 1999;86:1203-1209.
37. Nieforth KA, Nadeau R, Patel IH, Mould D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther. 1996;59:636-646.
38. Lockard JS, Levy RH, Congdon WC, DuCharme LL. Efficacy and toxicity of the solvent polyethylene glycol 400 in monkey model. Epilepsia. 1979;20:77-84.
39. Sadeghi T, Hartzog MG, Snell VE, et al. Busulfan and dimethylacetamide (DMA) are synergistic for induction of differentiation and apoptosis in human myeloid leukemia (AML) cells [abstract]. Proc Am Assoc Cancer Res. 2000;41:757.
40. Weiss AJ, Jackson LG, Carabasi RA, et al. Phase I study of dimethylacetamide. Cancer Chemother Rep. 1962;16:477-485.
41. de Vries EGE, Mulder NH, Postmus PE, Vriesendorp R, Willemse PHB, Sleijfer DT. High dose teniposide for refractory malignancies: a phase I study. Cancer Treat Rep. 1986;70:595-598.
42. Lotz JP, Machover DF, Malassagne B, Hingh B, et al. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosphamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. J Clin Oncol. 1991;9:1860-1870.
43. Lotz JP, Bouleuc C, Andre T, Touboul E, et al. Tandem high-dose chemotherapy with ifosphamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Cancer. 1996;77:2550-2559.
44. McLeod HL, Baker DK Jr, Pui C-H, Rodman JH. Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia. Cancer Chemother Pharmacol. 1991;29:15-54.
45. Litovitz T. The alcohols: ethanol, methanol, isopropanol, ethylene glycol. Pediatr Clin North Am. 1986;33:311-323.
46. Rodman JH, Abramowitch M, Sinkule JA, Hayes A, Rivera GK, Evans WE. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol. 1987;5:1007-1014.